Predictive and prognostic molecular markers for cancer medicine
Open Access
- 5 March 2010
- journal article
- Published by SAGE Publications in Therapeutic Advances in Medical Oncology
- Vol. 2 (2), 125-148
- https://doi.org/10.1177/1758834009360519
Abstract
Over the last 10 years there has been an explosion of information about the molecular biology of cancer. A challenge in oncology is to translate this information into advances in patient care. While there are well-formed routes for translating new molecular information into drug therapy, the routes for translating new information into sensitive and specific diagnostic, prognostic and predictive tests are still being developed. Similarly, the science of using tumor molecular profiles to select clinical trial participants or to optimize therapy for individual patients is still in its infancy. This review will summarize the current technologies for predicting treatment response and prognosis in cancer medicine, and outline what the future may hold. It will also highlight the potential importance of methods that can integrate molecular, histopathological and clinical information into a synergistic understanding of tumor progression. While these possibilities are without doubt exciting, significant challenges remain if we are to implement them with a strong evidence base in a widely available and cost-effective manner.This publication has 166 references indexed in Scilit:
- Clinical practice patterns and cost effectiveness of human epidermal growth receptor 2 testing strategies in breast cancer patientsCancer, 2009
- Epigenetic alterations in the breast: Implications for breast cancer detection, prognosis and treatmentSeminars in Cancer Biology, 2009
- Exonic expression profiling of breast cancer and benign lesions: a retrospective analysisThe Lancet Oncology, 2009
- A Genomic Strategy to Elucidate Modules of Oncogenic Pathway Signaling NetworksMolecular Cell, 2009
- Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trialThe Lancet, 2009
- Translational integrity and continuity: Personalized biomedical data integrationJournal of Biomedical Informatics, 2009
- Gene Expression Signatures, Clinicopathological Features, and Individualized Therapy in Breast CancerJAMA, 2008
- An E2F1-Dependent Gene Expression Program that Determines the Balance between Proliferation and Cell DeathCancer Cell, 2008
- PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patientsCancer Cell, 2004
- Gene expression profiling predicts clinical outcome of breast cancerNature, 2002